Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Novartis AG
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
No intraday reading yet this session.
Each disclosed tie as a share of both companies’ annual revenue. The bigger share is the side that would feel it if the relationship ended.
| Partner | % of their revenue | % of NVS revenue | Skew |
|---|---|---|---|
| RGNXRegenxbio Inc. | 98.00% | 0.29% | 333× |
| REGNRegeneron Pharmaceuticals, Inc. | 1.90% | 0.48% | 4.0× |
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In January 2020, we obtained a license from Novartis Pharma AG, or Novartis, to develop and commercialize an antibody cytokine engrafted protein, designated as IOV-3001.”
FILING10-K0001104659-26-018899cik 0001425205disclosed by IOVA
“Under the terms of the agreement, Novartis is providing Olema with ribociclib drug supply for the OPERA-02 trial, which we initiated in 2025.”
FILING10-K0001193125-26-107169cik 0001750284disclosed by OLMA
“In the second quarter of 2024, we completed a transaction with Novartis Pharma AG, or Novartis, which comprised a license agreement, or the Novartis License Agreement, and an asset agreement, or the Novartis Asset Agreement.”
FILING10-K0001628280-26-011226cik 0001655759disclosed by ARVN
“Health/beauty customers include GlaxoSmithKline, Bayer, Johnson & Johnson, Abbott, Novartis, L'Oréal S.A., Procter & Gamble and Colgate-Palmolive.”
FILING10-K0001408075-26-000009cik 0001408075disclosed by GPK
“Under the Novartis Agreement, and upon the closing of the transaction contemplated by the Novartis Agreement in January 2025, we received an upfront payment of $1.0 billion on the effective date and can receive up to $1.9 billion in development, regulatory and sales milestones, a 40% share of U.S. profits and losses, and tiered double-digit royalties on ex-U.S. sales.”
FILING10-K0001104659-26-017575cik 0001070081disclosed by PTCT
“Pursuant to the Settlement Agreement, we transferred our rights to future royalties on net sales of Beovu® to Novartis in exchange for a one-time payment of $8.0 million.”
FILING10-K0001193125-26-118532cik 0001782223disclosed by PYXS
“One customer (Novartis Gene Therapies) accounted for approximately 98%, 95% and 90% of our total revenues for the years ended December 31, 2024, 2023 and 2022, respectively.”
$167M relationship333× more of RGNX’s book than NVS’s
basisRGNX fy2025 · closed 2025-12 $170MNVS fy2025 · closed 2025-12 $56.7B
FILING10-K0000950170-25-038770cik 0001590877disclosed by RGNX
“In November 2024, we also entered into an expanded three-year software agreement with Novartis that substantially increases Novartis' access to our computational predictive modeling technology and enterprise informatics platform.”
FILING10-K0001490978-26-000010cik 0001490978disclosed by SDGR
“To date, our revenues have primarily consisted of consideration related to the Novartis Agreement and the Amgen Agreement, which we are accounting for under ASC 606.”
FILING10-K0001193125-26-089884cik 0001783328disclosed by TCRX
“In January 2018, through our subsidiary QED, we entered into a license agreement with Novartis International Pharmaceutical Ltd. ("Novartis"), for certain intellectual property rights, including patents and know-how, related to infigratinib for the treatment of patients with FGFR-driven diseases, including achondroplasia and hypochondroplasia.”
FILING10-K0001743881-26-000009cik 0001743881disclosed by BBIO
“Novartis obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals, Inc.”
FILING20-F0001114448-26-000004cik 0001114448
“In 2023, we entered into a royalty purchase agreement with Royalty Pharma to monetize a portion of our future SPINRAZA and pelacarsen royalties we are entitled to under our agreements with Biogen and Novartis, respectively.”
FILING10-K0000874015-26-000115cik 0000874015disclosed by IONS
“Net cash provided by financing activities was $114.0 million during the year ended December 31, 2024, primarily due to the $93.5 million in net proceeds from a public offering of common stock and warrants and $19.3 million in connection with the sale of common stock to Novartis in January 2024.”
FILING10-K0001104659-26-025197cik 0001640266disclosed by VYGR
“In addition, in January 2025, we and Novartis terminated the iscalimab license agreement.”
FILING10-K0001104659-26-030872cik 0000791908disclosed by XOMA
“Our operations have been financed primarily through the issuance and sale of common stock and convertible preferred stock and our prior collaboration with Novartis.”
FILING10-K0001746473-26-000037cik 0001746473disclosed by PLRX
“In addition, pursuant to the Novartis License, we are obligated to make certain milestone payments to Novartis in an aggregate amount of up to $62.0 million based on the achievement of certain clinical development, regulatory and sales milestones.”
FILING10-K0001193125-26-077442cik 0001831828disclosed by VERA
“Collaborative research with Novartis evaluated the pharmacodynamic effects of MIJ821 (onfasprodil) using our EEG analytics as an objective CNS biomarker in a Phase I first-in-human study, published in Clinical and Translational Science (2023).”
FILING10-K0001437749-26-010500cik 0000803578disclosed by AIFF
“On August 29, 2025, Novartis and the Company entered into a global licensing and collaboration agreement.”
FILING10-K0000879407-25-000029cik 0000879407disclosed by ARWR
“Royalties on sales of Novartis' Ilaris ® (canakinumab)”
$273M relationship4.0× more of REGN’s book than NVS’s
basisREGN fy2025 · closed 2025-12 $14.3BNVS fy2025 · closed 2025-12 $56.7B
FILING10-K0000872589-26-000008cik 0000872589disclosed by REGN
“Our life sciences customers range from the largest global pharmaceutical and biotechnology companies such as Bayer AG, Boehringer Ingelheim GmbH, Eli Lilly and Company, Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Novartis Pharma AG, to emerging growth pharmaceutical and biotechnology companies, including Alkermes Inc., Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and Idorsia Pharmaceuticals Ltd.”
FILING10-K0001393052-26-000014cik 0001393052disclosed by VEEV
“In addition, the Generate Platform’s modular capabilities underpin the confidential programs being developed in collaboration with Amgen Inc. ("Amgen") and Novartis Pharma AG ("Novartis").”
FILINGS-1/A0001193125-26-062362cik 0002100782disclosed by GENB
Watchlist prices, news filtered to it, and its next report on your desk.
Novartis AG has 16 disclosed suppliers and 5 disclosed customers. Each one is named in an SEC filing, either Novartis AG’s own annual report or the counterparty’s, and carries the sentence that discloses it.
NVS (Novartis AG) has 16 disclosed suppliers and 5 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: OLMA −4.96%, in healthcare.